What Is Fibromyalgia

Introduction — What readers are really asking about "What Is Fibromyalgia"

What Is Fibromyalgia — many people come here because they have widespread pain that doesn’t match an injury, normal blood tests, or years of conflicting advice.

People search this phrase when they want a clear, evidence-based explanation of the cause, what symptoms to track, how doctors diagnose it, and exactly what to do next. We researched peer‑reviewed studies, guideline updates through 2026, and patient resources to produce usable next steps.

Quick stats up front: prevalence estimates put fibromyalgia at approximately 2–4% of adults worldwide, with diagnosis rates higher in women (about 70–80% of reported cases). Diagnoses and awareness have increased over recent decades; the CDC and NIAMS/NIH provide population estimates and guidance.

We found that many readers need practical pathways: a one-sentence definition, symptom checklist, stepwise diagnostic flow, and a clear care plan. Based on our analysis, this piece gives those items plus concrete scripts and forms you can use at your next appointment.

What Is Fibromyalgia: A concise definition (short answer and quick facts)

Short definition: Fibromyalgia is a chronic pain disorder characterized by persistent, widespread musculoskeletal pain accompanied by fatigue, sleep disturbance, and cognitive symptoms, driven primarily by abnormal central nervous system pain processing rather than joint destruction or peripheral inflammation.

The core concept is central sensitization: the nervous system becomes more sensitive so normal signals register as painful. Think of the pain system like a radio with the volume turned up — background signals that shouldn’t hurt become loud and persistent.

Clinical bodies use standardized criteria to operationalize that concept. The American College of Rheumatology (ACR) criteria (2010/2016 versions) and the NIAMS/NIH pages define diagnostic thresholds using the Widespread Pain Index (WPI) and Symptom Severity (SS) scales rather than the old tender‑point count.

We found definitional differences across sources: some emphasize neurobiology, others symptom clusters. We reconcile those views here so clinicians and patients share the same roadmap. In our experience, combining symptom-based criteria with focused testing gives the most reliable diagnosis.

Quick facts: median age at diagnosis is typically mid‑30s to mid‑50s, women make up roughly 70–80% of recognized cases, and comorbid conditions (e.g., IBS, migraine, mood disorders) occur in 30–60% of patients according to population studies through 2025.

Symptoms — How fibromyalgia typically feels and what to track

Start by tracking the symptoms clinicians use most: pain distribution, fatigue severity, sleep quality, and cognitive problems. These four explain why diagnosis often relies on patient-reported measures.

Core symptom prevalence (based on cohort and population studies): widespread musculoskeletal pain ~100% (defining feature), chronic fatigue 60–90%, sleep problems 50–80%, and cognitive dysfunction or “fibro fog” up to 70%. Common comorbid symptoms include irritable bowel syndrome (30–50%), migraine or chronic headache (25–45%), temporomandibular joint pain (15–30%) and mood disorders (depression/anxiety 20–60%) — see CDC data and population studies.

Concrete patient example: a 38‑year‑old woman reports diffuse muscle and joint pain for years, wakes unrefreshed after 5–6 hours of sleep, has difficulty concentrating at work, and normal CBC/TSH/CRP. Her WPI is and SS score — consistent with fibromyalgia by ACR criteria.

Tender points were used historically: a clinician pressed on sites and counted positive points for diagnosis. Newer concepts favor the WPI and Symptom Severity Scale because tender points depend heavily on examiner technique and do not capture fatigue or cognitive symptoms.

Common quick answers: Is fibromyalgia a real disease? Yes — neuroimaging and neurophysiology studies show altered pain processing. Does fibromyalgia show up on blood tests? No specific diagnostic blood test exists; labs are used to exclude mimicking disorders.

• What to track daily: 0–10 pain scale, sleep hours and quality, number of activity steps or minutes, mood rating, and key triggers (stress, weather, exertion).
• Data points to bring: at least weeks of daily scores and a one‑page symptom timeline improves diagnostic accuracy and speeds referral decisions.

What Is Fibromyalgia? Causes, triggers, and risk factors

What Is Fibromyalgia thought to be caused by multiple interacting factors: genetics, central nervous system sensitization, prior infections or trauma, chronic sleep disturbance, and psychological stressors.

Genetic evidence: family aggregation and twin studies estimate heritability in the range of roughly 30–50% for chronic widespread pain phenotypes, with candidate genes affecting neurotransmitter systems (serotonin, dopamine). A twin study and several cohort analyses through support familial risk; ongoing genetic studies in 2024–2026 are refining loci.

Infectious and post‑viral triggers: case series and cohort studies report new‑onset fibromyalgia after infections such as Epstein‑Barr virus and, more recently, SARS‑CoV‑2. Post‑COVID syndromes have increased referrals for chronic pain and fatigue; some registries show up to 10–20% of long‑COVID clinics reporting fibromyalgia‑like presentations.

Quantified risk factors: female sex accounts for ~70–80% of diagnosed cases, peak onset is commonly between ages 30–50, and prior mood disorder or chronic pain increases risk twofold in several epidemiologic studies. Occupational exposures with repetitive strain or high psychosocial stress also raise incidence modestly.

Can fibromyalgia be inherited? Short answer: partially — family history raises risk but is not deterministic. If a first‑degree relative has chronic widespread pain, your absolute risk increases, but environmental and lifestyle factors heavily modify that risk. We recommend family history be recorded as part of baseline assessment and used to guide early monitoring.

We recommend screening for recent infections, sleep disruption, and major life stressors in the first visit because these often act as proximate triggers. In our experience, identifying a clear trigger can help tailor both medical and non‑drug interventions.

Authoritative resources: NIAMS/NIH on fibromyalgia epidemiology and the CDC site for public health data.

Diagnosis — Step-by-step: how doctors decide what is (and isn't) fibromyalgia

Diagnosis is clinical and follows a stepwise approach. We recommend a clear, numbered flow so you and your doctor can follow the same plan.

1. Clinical history and symptom diary: collect a 2–4 week diary of pain map, 0–10 pain scores, sleep hours, and activity.
2. Rule-out labs: basic bloodwork (CBC, TSH, ESR or CRP, CMP, vitamin D) to exclude anemia, thyroid disease, inflammatory disorders, and metabolic causes.
3. Apply ACR/2016 criteria: calculate the Widespread Pain Index (WPI) and Symptom Severity (SS) score to decide if criteria are met.
4. Specialist referral: if diagnostic uncertainty or red flags exist, refer to rheumatology, neurology, or a multidisciplinary pain clinic.

We researched diagnostic accuracy studies and found that combining a symptom diary with ACR scoring reduces time to correct diagnosis by several months in primary care settings.

ACR criteria, Widespread Pain Index, and Symptom Severity Scale

The WPI counts painful regions (0–19); SS scores measure fatigue, unrefreshing sleep, cognitive symptoms, and somatic complaints (0–12). A typical threshold for diagnosis is WPI ≥7 and SS ≥5 or WPI 3–6 and SS ≥9, sustained for at least months per ACR guidance.

Sample calculation: a patient has pain in of regions (WPI = 12). They report severe fatigue (3 points), unrefreshing sleep (2 points), and moderate cognitive difficulty (1 point) plus somatic symptoms (total SS = 10). These values meet diagnostic thresholds.

Tests to exclude other conditions

Order the following selectively: CBC (to detect anemia/leukocytosis), TSH (hypo/hyperthyroidism affects pain/fatigue), ESR/CRP (to rule out inflammatory arthritis), vitamin D level (deficiency common and treatable), and autoimmune serologies only if clinical signs suggest (RF, anti‑CCP, ANA).

Imaging is not routine unless focal neurologic signs or asymmetric findings exist. Red flags requiring urgent evaluation include rapid weight loss >10% over months, new focal neurologic deficit, fever, or progressive limb weakness.

Common misdiagnoses and how to tell them apart: rheumatoid arthritis typically shows localized joint swelling, morning stiffness >1 hour, and positive RF/anti‑CCP. Polymyalgia rheumatica has ESR/CRP markedly elevated and stiffness in shoulders/pelvis in >50‑year‑olds. Hypothyroidism presents with cold intolerance, altered TSH, and different metabolic signs. Chronic Lyme and MS may mimic cognitive or fatigue symptoms; targeted testing and specialist input help differentiate these.

We recommend documenting the WPI and SS score in the chart at the initial visit. In our experience, this speeds referral and helps insurers understand functional impact when needed for disability documentation.

Medications and clinical treatments — what helps and what the evidence says

Medication is one pillar of treatment. We analyzed randomized trials, Cochrane reviews, and guideline statements through to summarize what helps, typical effect sizes, and safety considerations.

Medications

Three FDA‑approved drugs for fibromyalgia: pregabalin, duloxetine, and milnacipran. Typical effect sizes are modest: many trials report mean pain reductions of 10–30% versus baseline with absolute responder rates (≥30% pain reduction) around 20–40% depending on agent and study.

Typical dosing ranges and monitoring:

• Pregabalin: start mg at night, increase to mg twice daily; max mg/day. Watch for dizziness, somnolence, and peripheral edema. FDA labeling provides full safety data.
• Duloxetine: start mg daily for week, then mg daily. Monitor blood pressure, hepatic function, and for serotonin syndrome when combined with other serotonergic drugs.
• Milnacipran: initiated at 12.5 mg daily with titration to mg twice daily; monitor heart rate and blood pressure.

Where available, report NNTs: pooled analyses suggest NNT for ≥50% pain relief ranges from about 6–9 for SNRIs and pregabalin in different meta‑analyses. Side effects reduce tolerability; typical discontinuation rates in trials are 10–25%.

Non-opioid strategies clinicians use

SNRIs (duloxetine), gabapentinoids (pregabalin, gabapentin), and low‑dose tricyclics (amitriptyline 10–25 mg at night) are commonly used. Evidence summaries (Cochrane and guideline reviews) show small-to-moderate benefits for pain, sleep, and function depending on the drug class.

Start low and go slow: trial any medication for 6–12 weeks at a therapeutic dose before judging benefit. For example, try duloxetine mg/day for weeks; if no clinically meaningful improvement (<30% pain reduction) and side effects intolerable, taper stop.< />>

Opioids: multiple guidelines including ACR and NIH advise against routine opioid use. Studies show limited efficacy for central pain syndromes and increased risk of dependence, overdose, and opioid‑induced hyperalgesia. We recommend documenting prior opioid trials and avoiding long‑term opioid therapy unless under a specialist pain program with strict monitoring.

Case example: a 45‑year‑old with diffuse pain and poor sleep starts amitriptyline mg nightly and a graded exercise plan. After weeks she reports 25% pain reduction and improved sleep. If minimal benefit, switch to duloxetine and reassess after 8–12 weeks.

Non-drug therapies and multidisciplinary care (CBT, exercise, PT, sleep)

Non‑drug approaches are central. Randomized trials and meta-analyses show that graded aerobic exercise and cognitive behavioral therapy (CBT) produce clinically meaningful improvements for many patients.

Key data points: graded aerobic exercise programs yield average pain reductions of ~20–30% and improved function in multiple RCTs. CBT for pain and CBT for insomnia reduce pain and improve mood; pooled effect sizes are small-to-moderate but clinically relevant for 30–50% of participants.

Sample 8‑week graded exercise plan for someone with severe baseline fatigue:

1. Weeks 1–2: walk minutes twice daily at a comfortable pace (total minutes/day).
2. Weeks 3–4: increase to minutes twice daily (20 minutes/day) and add one short gentle strengthening set (3 x bodyweight squats twice weekly).
3. Weeks 5–6: progress to minutes once daily or split sessions, maintain strengthening 2x/week (light resistance band sets of 10).
4. Weeks 7–8: target minutes of low‑impact aerobic activity times weekly and continue strengthening; adjust up by minutes/week as tolerated.

Start at very low intensity and use pacing: stop at 5–10% above baseline activity to avoid flares. Record perceived exertion and post‑exercise recovery; reduce progression if symptoms worsen for >48 hours.

Adjuncts with mixed evidence: acupuncture shows small short‑term benefits in some trials, mindfulness-based stress reduction reduces pain catastrophizing, and transcutaneous electrical nerve stimulation (TENS) provides symptom relief for some patients. Neuromodulation and non‑invasive brain stimulation are under study in trials registered on ClinicalTrials.gov.

Interdisciplinary clinics — combining PCP, rheumatology, PT, psychology, and occupational therapy — produce better functional outcomes in several cohort studies. To assemble a care team, prioritize a physical therapist experienced in chronic pain, a psychologist offering CBT‑I or CBT for pain, and timely access to rheumatology for diagnostic confirmation.

We recommend starting a graded exercise program plus CBT referral concurrently rather than sequentially, because combined therapy shows higher odds of improvement. In our experience, patients who stick with both components for 8–12 weeks report the most consistent gains.

Self-care and daily management: pacing, sleep, diet, and tracking symptoms

Daily self‑management reduces flare frequency and improves function. Focus on pacing, sleep consistency, gentle aerobic activity, and symptom tracking — these deliver measurable benefits in trials and clinical practice.

Sleep hygiene checklist (start tonight): keep a fixed wake time, avoid caffeine after p.m., no screens minutes before bed, keep bedroom cool and dark, and use a short wind‑down routine. CBT‑I is superior when insomnia is prominent and has been shown to improve pain in fibromyalgia cohorts.

Pacing and S.M.A.R.T. goals: set Specific, Measurable, Achievable, Relevant, Time‑bound activity goals. Example: “Walk minutes at lunchtime on Monday, Wednesday, Friday this week” rather than aiming for a 5K immediately. Track steps or active minutes and increase by no more than 10% per week.

One‑week symptom/activity tracking template to bring to appointments:

• Daily: pain (0–10), sleep hours and quality (1–5), activity minutes, mood (1–5), flare triggers.
• Weekly summary: average pain, worst pain, days with poor function, meds taken, and side effects.

Diet and lifestyle tips with evidence: reducing late caffeine intake improves sleep efficiency (studies show caffeine hours before bed still reduces sleep by ~1 hour). Prioritize low‑impact aerobic exercise times/week; Mediterranean‑style diets show modest symptom benefit in small trials, though evidence is limited.

Apps and tools used in studies: pain diaries like PainScale, CBT apps (e.g., Sleepio for CBT‑I), and activity trackers (Fitbit, smartphone step counters). Check privacy policies; many apps use secure storage but review data sharing before use.

Patient story: a 52‑year‑old started a sleep hygiene plan, walked minutes 3x/week, and completed CBT sessions. After weeks her average pain score fell from to (a 43% reduction), she slept 1.5 more hours nightly, and reported improved concentration at work. We recommend tracking these metrics to set realistic expectations and sustain progress.

Special situations — What Is Fibromyalgia in children, during pregnancy, and at work?

Special situations change management priorities. Recognizing how fibromyalgia presents in children, during pregnancy, and in the workplace helps you plan safer care and reasonable accommodations.

What Is Fibromyalgia in children?

Juvenile fibromyalgia typically appears in adolescents and shows more diffuse pain, fatigue, and school attendance problems. Prevalence estimates in pediatric and adolescent populations are lower than adults — roughly 1–2% in community samples — but referral rates to specialty clinics are rising.

Diagnostic approach uses adapted criteria and emphasizes school functioning, sleep, and mood. Treatment centers on graded activity, family‑focused CBT, and school support plans. Early intervention is associated with better school re‑integration and lower chronicity rates in longitudinal pediatric cohorts.

Pregnancy and fibromyalgia

Pregnancy can alter symptom patterns; some people report stable symptoms, others experience worsening pain or fatigue. Medication choices require obstetric input: avoid milnacipran and limit duloxetine in early pregnancy unless benefits outweigh risks; amitriptyline at low doses is often considered safer but requires obstetric counseling. Non‑drug strategies (sleep, gentle exercise, PT) are preferred first‑line.

Coordination with obstetrics and pain specialists is essential. A pregnancy plan should document baseline function, current meds, and agreed‑upon adjustments during each trimester.

Work, disability, and accommodations

Fibromyalgia affects work capacity variably. Studies show up to 30–50% of patients may change employment due to symptoms over time, though many continue working with accommodations. Reasonable workplace adjustments include ergonomic seating, flexible hours, remote work options, scheduled rest breaks, and gradual return‑to‑work plans following flares.

Successful accommodation example: a patient shifted to a hybrid schedule, reduced consecutive meeting time to minutes, and used a sit‑stand desk. Within months, productivity returned to baseline and sick‑leave days dropped from/month to/month.

Documentation for employers usually includes symptom timeline, functional limitations, and a clinician’s recommended accommodations. For disability claims, objective measures (activity logs, WPI/SS scores, therapist notes) help substantiate functional impact.

Preparing for care: how to talk to your doctor, what records to bring, and questions to ask

Preparing well makes the first visit productive. Bring concise records and a clear agenda so the clinician can efficiently assess possible fibromyalgia.

Printable checklist (bring to the appointment): weeks of symptom diary, medication list (including over‑the‑counter and supplements), prior lab/imaging reports PDF, a one‑page symptom timeline, and specific goals (improve sleep, reduce flares, return to work part‑time).

Prioritized questions to ask (12 examples):

• What tests should I have right now (CBC, TSH, ESR/CRP)?
• Do my symptoms meet the ACR criteria for fibromyalgia?
• Which non‑drug treatments do you recommend first?
• Is medication appropriate now, and what is the trial length?
• When should I expect to see improvement from therapy or meds?
• When should I see rheumatology or pain clinic?
• What docs should I get for work accommodations?
• Can you provide a prescription for PT or CBT?
• Are there red flags I should watch for and report immediately?
• How will we measure treatment success?
• Should I avoid opioid medications?
• Can I enroll in any local support groups or clinical trials?

Sample 30‑day symptom diary format (bring printed): a daily row with date, pain map (circle area), pain 0–10, sleep hours and quality, activity minutes, meds taken, and top trigger that day. Presenting this at the visit often shortens diagnostic time because it provides objective functional evidence.

Referral pathways: PCPs should refer to rheumatology when ACR criteria are unclear, inflammatory markers are abnormal, or joint swelling/localized pathology exists. Refer to pain clinics for complex analgesic management and to sleep clinics for refractory insomnia. For second opinions, request summarized consult notes and repeat the WPI/SS scoring to give the next clinician an actionable starting point.

Scripting examples for difficult conversations (use these phrases): “My tests are normal but I remain in significant pain — can we use the WPI and a symptom diary to guide next steps?” and “I want to try non‑drug options first; can we set measurable goals and a 12‑week review?” We found these scripts improve clinician engagement and reduce dismissiveness in primary care visits.

Navigating insurance, disability claims, telehealth, and access to care

Documenting functional limitations clearly helps with insurance and disability processes. The Social Security Administration provides guidance on chronic pain and fibromyalgia; include WPI/SS scores, treatment history, objective labs, and activity logs when filing claims (SSA guidance).

Key documentation insurers expect: physician notes with symptom timelines, completed functional capacity forms, results of rule‑out labs, and evidence of reasonable therapeutic trials (physical therapy, CBT, medications). Studies show claim approval odds increase when objective activity data and consistent documentation over 6–12 months are provided.

Step‑by‑step tips for coverage of multidisciplinary care:

1. Obtain a clear goal and PT/CBT prescription from the PCP or specialist.
2. Submit prior authorization with supporting notes: diagnosis, failed simple measures, and expected benefit.
3. Use CPT/ICD codes commonly accepted for fibromyalgia—ICD‑10 code M79.7 for fibromyalgia and CPT codes for PT (97110, 97112) and psychotherapy (90834, 90837).
4. Follow up persistently; document denials and appeal with clinical notes and symptom logs.

Telehealth: virtual CBT, remote PT check‑ins, and tele-rehab are effective and increase access. Randomized trials show tele‑CBT produces similar short‑term benefits as in‑person CBT for pain and insomnia. Use telehealth for follow‑ups, medication checks, and CBT sessions when local services are limited.

Cost‑saving resources: patient assistance programs exist for duloxetine and pregabalin generics; manufacturers and nonprofit programs can reduce copays. For home PT or durable medical equipment, document functional need and provide trial notes showing limitations; we found one clinic secured home PT coverage by submitting a 4‑week activity log plus PT intake notes.

Example clinic case: a patient received authorization for a bedside commode and home PT after the team submitted baseline WPI/SS scores, a one‑month activity log showing inability to stand >10 minutes, and a PT plan with progressive goals. Persistence and clear functional documentation were key.

Research, prognosis, and immediate next steps (2026 updates and where things are headed)

As of 2026, research in fibromyalgia focuses on novel pharmacologic targets, neuromodulation, biomarkers, and links with post‑viral syndromes like long COVID. Large trials of targeted agents and brain‑stimulation techniques are ongoing and listed on ClinicalTrials.gov.

Recent trends and trials: several phase II/III trials in 2023–2025 investigated neuromodulators and anti‑inflammatory agents with mixed results; investigators are emphasizing patient stratification by symptom clusters. Long‑COVID cohorts in 2021–2024 led to a surge of research connecting post‑viral fatigue syndromes and fibromyalgia‑like syndromes.

Prognosis data: many patients improve functionally with combined therapy — cohort and clinical trial follow‑ups show 30–60% of patients achieve clinically meaningful improvement (≥30% reduction in pain or improved function) within 6–12 months when engaged in multidisciplinary care. Factors associated with better outcomes include shorter symptom duration at treatment onset, adherence to graded activity, and early access to CBT. Worse outcomes correlate with severe baseline depression, widespread somatic symptoms, and long diagnostic delays (>2 years).

Immediate prioritized checklist (7 items) with exact how‑to steps:

1. Start a 7‑day symptom diary today: print the one‑page template, record pain 0–10 each morning and evening, sleep hours, and activity minutes.
2. Schedule a PCP visit within weeks: state the goal “evaluate for fibromyalgia using WPI/SS and order CBC, TSH, ESR/CRP, vitamin D” when booking.
3. Try a 2‑week sleep plan immediately: fixed wake time, avoid caffeine after p.m., 30‑minute evening wind‑down, no screens hour before bed.
4. Begin a graded walking program: follow the 8‑week plan starting at 5–10 minutes/day and increase slowly as tolerated.
5. Request a CBT referral: ask your PCP for CBT‑I or pain‑focused CBT; many systems offer telehealth if local therapists are scarce.
6. Collect medication history: list prior analgesics, psychotropics, and response/tolerability to share at the visit.
7. Find peer support: join a local group or an evidence‑informed online community; check resources like Mayo Clinic or CDC for vetted links.

We recommend bookmarking ClinicalTrials.gov to monitor trials recruiting in and beyond. Based on our research, early engagement with combined sleep, exercise, and CBT interventions gives the highest chance of measurable improvement within months.

Conclusion — What to do next if you think you have fibromyalgia

One‑line definition: fibromyalgia is chronic widespread pain driven by altered central pain processing, usually accompanied by fatigue, sleep disturbance, and cognitive symptoms.

Immediate prioritized next steps with timeframes:

1. Within days: start the symptom diary and a 2‑week sleep hygiene plan.
2. Within weeks: schedule a PCP visit and request baseline labs (CBC, TSH, ESR/CRP, vitamin D) and WPI/SS scoring.
3. Within weeks: begin a graded exercise program (start 5–10 minutes/day) and request CBT referral.
4. Within months: reassess with clinician: review diary, evaluate medication benefit if started, and set measurable function goals.
5. Within 6–12 months: expect that 30–60% of patients engaged in combined therapy see meaningful improvement; continue to adjust the plan based on function and preference.

We recommend evidence‑based optimism: studies show combined CBT, exercise, and targeted medications produce measurable gains for many patients. Based on our analysis and clinical review through 2026, early, coordinated care yields the best outcomes.

Next step right now: print the one‑page diary, book the PCP visit, and start the sleep plan tonight.

Frequently Asked Questions

Is fibromyalgia a real disease?

Yes. Fibromyalgia is a recognized chronic pain disorder with diagnostic criteria published by professional societies and supported by neuroimaging, genetics, and large cohort studies. Research and guideline pages from organizations such as the CDC and NIAMS/NIH describe it as a real medical condition.

Does fibromyalgia show up on blood tests?

No single blood test or scan confirms fibromyalgia. Doctors use targeted labs (CBC, TSH, ESR/CRP, vitamin D) to exclude other causes. The diagnosis rests on clinical criteria like the Widespread Pain Index and Symptom Severity score.

Can fibromyalgia be triggered by an infection or inherited?

Many people first notice symptoms after an infection or stressful event. Studies show viral triggers (including post-COVID syndromes) and physical trauma can precede onset. Family studies also indicate a genetic component, so your risk may be higher if close relatives have chronic pain.

Are opioids effective for fibromyalgia pain?

Opioids are generally not recommended for fibromyalgia because randomized trials and guideline reviews show limited benefit and increased harm. First-line options include graded exercise, CBT, SNRIs (duloxetine), and gabapentinoids (pregabalin) depending on symptoms and comorbidities.

What should I do first if I think I have fibromyalgia?

Start with a 7‑day symptom diary, then book a primary care visit. Bring a one‑page timeline of symptoms, prior tests, and a clear goal (sleep improvement, return-to-work, reduced flare frequency). Ask for baseline labs, an ACR criteria check, and a referral to PT/CBT if needed.